Display options
Cite
Kindernay L, Farkasova V, Neckar J, et al. Impact of Maturation on Myocardial Response to Ischemia and the Effectiveness of Remote Preconditioning in Male Rats. Int J Mol Sci. 2021;22(20)doi: 10.3390/ijms222011009.
Kindernay, L., Farkasova, V., Neckar, J., Hrdlicka, J., Ytrehus, K., & Ravingerova, T. (2021). Impact of Maturation on Myocardial Response to Ischemia and the Effectiveness of Remote Preconditioning in Male Rats. International journal of molecular sciences, 22(20), . https://doi.org/10.3390/ijms222011009
Kindernay, Lucia, et al. "Impact of Maturation on Myocardial Response to Ischemia and the Effectiveness of Remote Preconditioning in Male Rats." International journal of molecular sciences vol. 22,20 (2021). doi: https://doi.org/10.3390/ijms222011009
Kindernay L, Farkasova V, Neckar J, Hrdlicka J, Ytrehus K, Ravingerova T. Impact of Maturation on Myocardial Response to Ischemia and the Effectiveness of Remote Preconditioning in Male Rats. Int J Mol Sci. 2021 Oct 12;22(20). doi: 10.3390/ijms222011009. PMID: 34681669; PMCID: PMC8540346.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Sci. 2021 Oct 12;22(20). doi: 10.3390/ijms222011009.

Impact of Maturation on Myocardial Response to Ischemia and the Effectiveness of Remote Preconditioning in Male Rats.

International journal of molecular sciences

Lucia Kindernay, Veronika Farkasova, Jan Neckar, Jaroslav Hrdlicka, Kirsti Ytrehus, Tanya Ravingerova

Affiliations

  1. Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, 9 Dúbravská cesta, 84104 Bratislava, Slovakia.
  2. Institute of Physiology, Academy of Sciences of the Czech Republic, 1083 Víde?ská, 142 00 Prague, Czech Republic.
  3. Department of Medical Biology, UiT The Arctic University of Norway, 18 Hansine Hansens veg, 9019 Tromsø, Norway.

PMID: 34681669 PMCID: PMC8540346 DOI: 10.3390/ijms222011009

Abstract

Aging attenuates cardiac tolerance to ischemia/reperfusion (I/R) associated with defects in protective cell signaling, however, the onset of this phenotype has not been completely investigated. This study aimed to compare changes in response to I/R and the effects of remote ischemic preconditioning (RIPC) in the hearts of younger adult (3 months) and mature adult (6 months) male Wistar rats, with changes in selected proteins of protective signaling. Langendorff-perfused hearts were exposed to 30 min I/120 min R without or with prior three cycles of RIPC (pressure cuff inflation/deflation on the hind limb). Infarct size (IS), incidence of ventricular arrhythmias and recovery of contractile function (LVDP) served as the end points. In both age groups, left ventricular tissue samples were collected prior to ischemia (baseline) and after I/R, in non-RIPC controls and in RIPC groups to detect selected pro-survival proteins (Western blot). Maturation did not affect post-ischemic recovery of heart function (Left Ventricular Developed Pressure, LVDP), however, it increased IS and arrhythmogenesis accompanied by decreased levels and activity of several pro-survival proteins and by higher levels of pro-apoptotic proteins in the hearts of elder animals. RIPC reduced the occurrence of reperfusion-induced ventricular arrhythmias, IS and contractile dysfunction in younger animals, and this was preserved in the mature adults. RIPC did not increase phosphorylated protein kinase B (p-Akt)/total Akt ratio, endothelial nitric oxide synthase (eNOS) and protein kinase Cε (PKCε) prior to ischemia but only after I/R, while phosphorylated glycogen synthase kinase-3β (GSK3β) was increased (inactivated) before and after ischemia in both age groups coupled with decreased levels of pro-apoptotic markers. We assume that resistance of rat heart to I/R injury starts to already decline during maturation, and that RIPC may represent a clinically relevant cardioprotective intervention in the elder population.

Keywords: ischemia/reperfusion injury; maturation; protective cell signaling; remote ischemic preconditioning

References

  1. Physiol Res. 2015;64(Suppl 5):S685-96 - PubMed
  2. Am J Physiol Regul Integr Comp Physiol. 2002 Feb;282(2):R423-30 - PubMed
  3. Cell Physiol Biochem. 2018;45(5):2107-2121 - PubMed
  4. Basic Res Cardiol. 2006 May;101(3):235-43 - PubMed
  5. Clin Sci (Lond). 2011 May;120(10):451-62 - PubMed
  6. J Appl Physiol (1985). 2017 May 1;122(5):1095-1105 - PubMed
  7. Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2056-63 - PubMed
  8. Cardiovasc Res. 2017 May 1;113(6):564-585 - PubMed
  9. Mol Med Rep. 2016 Jan;13(1):197-205 - PubMed
  10. J Clin Invest. 2004 Jun;113(11):1535-49 - PubMed
  11. Cardiovasc Diabetol. 2017 Apr 26;16(1):57 - PubMed
  12. Physiol Res. 2016 Sep 19;65 Suppl 1:S55-64 - PubMed
  13. Cardiovasc Res. 2006 May 1;70(2):325-34 - PubMed
  14. Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1290-8 - PubMed
  15. Anesth Pain Med. 2017 Jan 11;7(1):e42505 - PubMed
  16. Heart Fail Rev. 2007 Dec;12(3-4):217-34 - PubMed
  17. Int J Prev Med. 2013 Jun;4(6):624-30 - PubMed
  18. Circulation. 1986 Nov;74(5):1124-36 - PubMed
  19. J Cardiothorac Vasc Anesth. 2017 Aug;31(4):1223-1226 - PubMed
  20. Mech Ageing Dev. 2005 May;126(5):535-50 - PubMed
  21. Eur J Pharmacol. 2017 Nov 5;814:9-17 - PubMed
  22. J Transl Med. 2018 Apr 27;16(1):112 - PubMed
  23. Clin Sci (Lond). 2018 Jul 9;132(13):1367-1382 - PubMed
  24. Cardiovasc Res. 2013 Sep 1;99(4):694-704 - PubMed
  25. FASEB J. 2006 Apr;20(6):791-3 - PubMed
  26. Anal Biochem. 1976 May 7;72:248-54 - PubMed
  27. Can J Physiol Pharmacol. 2013 Aug;91(8):640-7 - PubMed
  28. PLoS One. 2016 Oct 21;11(10):e0165123 - PubMed
  29. Basic Res Cardiol. 2013 Jan;108(1):314 - PubMed
  30. Int J Exp Pathol. 2016 Feb;97(1):66-74 - PubMed
  31. Circulation. 1997 Jun 3;95(11):2559-66 - PubMed
  32. Cardiovasc Res. 1988 Sep;22(9):656-65 - PubMed
  33. Exp Physiol. 2016 Jun 1;101(6):708-16 - PubMed
  34. Pharmacol Rev. 2014 Oct;66(4):1142-74 - PubMed
  35. Cardiovasc Drugs Ther. 2012 Apr;26(2):87-93 - PubMed
  36. Biochem Biophys Res Commun. 2017 Jun 24;488(2):278-284 - PubMed
  37. Int J Cardiol. 2015 Apr 1;184:140-151 - PubMed
  38. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):178-188 - PubMed
  39. Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H1978-87 - PubMed
  40. Br J Pharmacol. 2020 Dec;177(23):5270-5286 - PubMed
  41. Naunyn Schmiedebergs Arch Pharmacol. 2016 Jan;389(1):1-9 - PubMed
  42. Shock. 2011 Jul;36(1):45-53 - PubMed
  43. Circ Res. 1994 Feb;74(2):299-309 - PubMed
  44. J Gerontol A Biol Sci Med Sci. 2013 Apr;68(4):395-403 - PubMed
  45. PLoS One. 2010 Apr 09;5(4):e10085 - PubMed
  46. Cardiovasc Res. 2009 Jul 15;83(2):247-61 - PubMed
  47. Cell Physiol Biochem. 2017;41(1):22-32 - PubMed
  48. J Am Coll Cardiol. 2006 Jun 6;47(11):2277-82 - PubMed
  49. J Cell Mol Med. 2018 Feb;22(2):926-935 - PubMed
  50. Mol Med Rep. 2014 Jul;10(1):536-42 - PubMed
  51. Heart. 2009 Oct;95(19):1567-71 - PubMed
  52. J Thorac Cardiovasc Surg. 2014 Mar;147(3):1049-55 - PubMed
  53. Cardiovasc Res. 2002 Dec;56(3):443-53 - PubMed
  54. Lancet. 2007 Aug 18;370(9587):575-9 - PubMed
  55. Shock. 2017 Mar;47(3):363-369 - PubMed
  56. Mol Cell Biochem. 2007 Mar;297(1-2):111-20 - PubMed
  57. Cureus. 2020 Jul 23;12(7):e9349 - PubMed
  58. Life Sci. 2016 May 1;152:238-43 - PubMed
  59. Med Sci Monit. 2019 Mar 08;25:1769-1779 - PubMed

Publication Types

Grant support